ORR per BICR was higher, with the complete response rate ~ 4 times higher for NIVO + IPI versus Chemo in patients with tumor-cell PD-L1 ≥ 1% and in all randomized patients (Table 2). The gene discussed is CD274; the disease is neoplasm.